Login to Your Account



Optimer Expands Astellas Antibiotic Deal to Japan

By Staff Reports


Friday, March 30, 2012
Optimer Pharmaceuticals Inc. has earned analyst and investor kudos for its successful launch of Dificid (fidaxomicin). The macrolide antibiotic for Clostridium difficile Infection (CDI) had fourth quarter 2011 net sales of about $11 million and has bucked the biotech trend of underperforming analyst launch estimates.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription